Surgical approach of breast cancer: advances and limitations

New approaches in surgical methods and systematic therapy have led to a better prognosis for women including a better quality of life. Modified radical mastectomy, the treatment of choice in breast cancer, tends to be replaced by breast-conservation surgical procedures. Furthermore, the value of axillary lymph node dissection has been questioned. Sentinel lymph node biopsy has contributed in staging of the axilla in order to avoid extensive operations

Surgery; Breast cancer; Mastectomy; Classification; Lymphadenectomy.

[1] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[2] Key Τ., Verkasalo P., Banks E.: “Epidemiology of breast cancer”. Lancet Oncol., 2001, 2, 133.

[3] Hoffmann J., Wallwiener D.: “Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients”. BMC Cancer, 2009, 9, 108.

[4] Sakorafas G., Siafoleas M.: “Breast cancer surgery: an historical narrative. Part I. From prehistoric times to Renaissance”. Eur. J. Cancer Care, 2009, 18, 530.

[5] Sakorafas G., Siafoleas M.: “Breast cancer surgery: an historical narrative. Part II. 18th and 19th centuries”. Eur. J. Cancer Care, 2010, 19, 6.

[6] Ekmektzoglou K., Xanthos T., German V., Zografos G.: “Breast cancer: from the earliest times through to the end of the 20th century”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 145, 3.

[7] Sainsbury J., Anderson T.J., Morgan D.: “ABC of breast diseases: breast cancer”. BMJ, 1994, 309, 1150.

[8] Bostwick J.: “Breast reconstruction following mastectomy”. CA Cancer J. Clin., 1995, 45, 289.

[9] Mascaro A., Farina M., Gigli R., Vitelli C., Fortunato L.: “Recent advances in the surgical care of breast cancer patients”. World J. Surg. Oncol., 2010, 8, 5.

[10] Babiera G., Simmons R.: “Nipple-areolar complex-sparing mastectomy: feasibility, patient selection, and technique”. Ann. Surg Oncol., 2010, 17, 245.

[11] Wéber B., Demange L., Rigaud C., Fernandes-Valoni A.: “Que restet- il des indications de mastectomie totale pour cancer?” Bull Cancer, 1998, 85, 755.

[12] Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., et al.: “Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer”. N. Engl. J. Med., 2002, 347, 1227.

[13] Moore M., Kinne D.: “The surgical management of primary invasive breast cancer”. CA Cancer J. Clin., 1995, 45, 279.

[14] Bland K.I., Menck H.R., Scott-Conner C. E., Morrow M., Winchester D.J., Winchester D. P.: “The National Cancer Data Base 10
year survey of breast carcinoma treatment at hospitals in the United States”. Cancer, 1998, 83, 1262.

[15] Poggi M.M., Danforth D.N., Sciuto L.C., Smith S.L., Steinberg S.M., Liewehr D.J., Altemus R.M.: “Eighteen- year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy”. Cancer, 2003, 98, 697.

[16] Lazovich,D., Solomon C.C., Thomas D.B., Moe R.E., White E.: “Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma”. Cancer, 1999, 86, 628.

[17] Mook S, Knauer M, Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., et al.: “Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature”. Ann. Surg. Oncol., 2010, 17, 1406.

[18] Jatoi I., Proschan M.: “Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results”. Am. J. Clin. Oncol., 2005, 28, 289.

[19] Bauman L., Barth R., Rosenkranz K.: “Breast conservation in women with multifocal-multicentric breast cancer: is it feasible?” Ann. Surg. Oncol., 2010, 17, 325.

[20] Rosen P.P., Groshen S., Kinne D.W., Norton L.: “Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up”. J. Clin. Oncol., 1993, 11, 2090.

[21] Perez C.: “Breast conservation therapy in patients with Stage T1–T2 breast cancer: current challenges and opportunities”. Am. J. Clin. Oncol., 2010, 33, 500.

[22] De Lorenzi F.: “Oncoplastic surgery: the evolution of breast cancer treatment”. Breast J., 2010, 16, S20.

[23] Silverstein M.: “How I do it: oncoplastic breast-conservation surgery”. Ann Surg. Oncol., 2010, 17, 242.

[24] Iwuchukwu O., Harvey J., Dordea M., Critchley A., Drew P.: “The-role of oncoplastic therapeutic mammoplasty in breast cancer surgery- a review”. Surg Oncol., 2012, 21, 133.

[25] Pinsolle V., Grinfeder C., Mathoulin-Pelissier S., Faucher A.: “Complications analysis of 266 immediate breast reconstructions”. J. Plast. Reconstr. Aesthet. Surg., 2006, 59, 1017.

[26] Sclafani L., Baron R.: “Sentinel lymph node biopsy and axillary dissection: added morbidity of the arm, shoulder and chest wall after mastectomy and reconstruction”. Cancer J., 2008, 14, 216.

[27] Samphao S., Eremin J., El- Sheemy M., Eremin O.: “Management of the axilla in women with breast cancer”. Lancet Oncol., 2007, 8, 331.

[28] Giuliano A., Kirgan D., Guenther M., Morton D.: “Lymphatic mapping and sentinel lymphadenectomy for breast cancer”. Ann. Surg., 1994, 220, 391.

[29] Lyman G., Giuliano A., Somerfield M., Benson Al B., Bodurka D., Burstein H., et al.: “American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer”. J. Clin. Oncol., 2005, 23, 7703.

[30] Del Valle V., Bermejo Alvarez M., Marauri P., Femenandez R.: “Pneumothorax secondary to axillary sentinel lymph node biopsy”. Rev. Esp. Anestesiol. Reanim., 2008, 55, 185.

[31] Benson J., Querci della Rovere G.: “Management of the axilla in women with breast cancer”. Lancet Oncol., 2007, 8, 331.

[32] Patani N., Dwek M., Douek M.: “Predictors of axillary lymph node metastasis in breast cancer: a systematic review”. EJSO, 2007, 33, 409.

[33] Collins C.: “The sentinel node in breast cancer”. Cancer Imaging, 2008, 8, S10.

[34] Roumen R., Geuskens L., Valkenburg J.: “In search of the true sen tinel node by different injection techniques in breast cancer patients. EJSO, 1999, 25, 347.

[35] Unal B., Gur A., Kayiran O., Johnson R., Ahrendt G., Bonaventura M., et al.: “Models for predicting non
sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system”. Int. J. Clin. Pract., 2008, 62, 1785.

[36] Orr R.: “The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis”. Ann. Surg. Oncol., 1999, 6, 109.

[37] Giuliano A., Hunt K., Ballman K., Beitsch P., Whitworth P., Blumencranz P., et al.: “Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial:. JAMA, 2011, 305, 569.

[38] Giuliano A., McCall L., Beitsch P., Whitworth P., Blumercranz P., Leitch A., et al.: “Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial”. Ann. Surg., 2010, 252, 426.

[39] Klauber-De More N., Tan L., Liberman L., Kaptain S., Fey J., Borgen P., et al.: “Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?” Ann. Surg. Oncol., 2000, 7, 636.

[40] Edge S., Byrd D., Compton C., Fritz, A.G., Greene, F.L., Trotti, A. (eds). AJCC Cancer Staging Handbook. 7th ed, New York, NY: Springer-Verlag, 2010.

[41] Stebbing J., Delaney G., Thompson A.: “Breast cancer (non-metastatic)”. BMJ Clin. Evid., 2007, 2007, pii: 0102.

[42] Rosen P.P., Fracchia A.A., Urban J.A., Schotenfeld D., Robbins G.F.: “Residual” mammary carcinoma following simulated partial mastectomy”. Cancer, 1975, 35, 739.

[43] Shenkier T., Weir L., Levine M., Olivotto I., Whelan T., Renyo L., et al.: “Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer”. CMAJ, 2004, 170, 983.

[44] Cady B., Nathan N., Michaelson J., Golshan M., Smith B.: “Matched pair analyses of stage IV breast cancer with or without resection of primary breast site”. Ann. Surg. Oncol., 2008, 15, 3384.

[45] Pagani O., Senkus E., Wood W., Colleoni M., Cufer T., Kyriakides S., et al.: “International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?” J. Natl. Cancer Inst., 2010, 102, 456.

[46] Gonzalez-Angulo A., Hennessy B., Broglio K., Meric-Bernstam F., Christofanilli M., Giordano S., et al.: “Trends for inflammatory breast cancer: is survival improving?” Oncologist, 2007, 12, 904.

[47] Woodward W., Cristofanilli M.: “Inflammatory breast cancer”. Semin. Radiat. Oncol., 2009, 19, 256.

[48] Robertson F., Bondy M., Yang Y., Yamauchi H., Wiggins S., Kamrudin S., et al.: “Inflammatory breast cancer: the disease, the biology, the treatment”. CA Cancer J. Clin., 2010, 60, 351.

[49] Kumar S., Sacchini V.: “The surgical management of ductal carcinoma in situ”. Breast J., 2010, 16, S49.